Role of CYP2D6 testing in selection of endocrine therapy for breast cancer

Pharmacogenomics

Volumn 8, Issue 1, 2007, Pages 1-3

  Stebbing, Justin ^a,c   Stearns, Vered ^b   Davidson, Nancy E ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIDEPRESSANT AGENT; AROMATASE INHIBITOR; CYTOCHROME P450 2D6; DRUG METABOLITE; ENDOXIFEN; EXEMESTANE; FLUOXYMESTERONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALLELE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HOT FLUSH; HUMAN; INDIVIDUALIZATION; MONOTHERAPY; OVERALL SURVIVAL; PHARMACOGENETICS; PHENOTYPIC VARIATION; RECURRENT CANCER; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS;

EID: 33846552983     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.1.1     Document Type: Editorial

References (27)

1. Stebbing J, Bower M: What can oncologists learn from HIV? Lancet Oncol. 4, 438-445 (2003).
2. Stebbing J, Bower M: Comparative pharmacogenomics of antiretroviral and cytotoxic, treatments. Lancet Oncol. 7, 61-68 (2006).
3. Bowen RL, Stebbing J, Jones LJ: A review of the ethnic differences in breast cancer: Pharmacogenomics, 935-942 (2006).
4. Hamelin BA, Bouayad A, Methot J et al.: Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin. Pharmol. Ther. 67, 466-477 (2000).
5. Forbes JF: The control of breast cancer: the role of tamoxifen. Semin. Oncol. 24, S1-5-S1-19 (1997).
6. Michalides R, Griekspoor A, Balkenende A et al.: Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell 5, 597-605 (2004).
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects ofthemotherapy and hormonal ffierapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
8. DeVita VT Jr: The concept of cure. Nat. Clin. Pract. Oncol. 3, 59 (2006).
9. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S. Ueland PM: Distribution of 4-hydro)-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49, 2175-2183 (1989).
10. Sridar C, Kent UM, Notley LM, Gillam EM, Hollenberg PF: Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol. Exp. Ther. 301, 945-952 (2002).
11. Coller JK, Krebsfaenger N, Klein K et al.: The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. & J Clin. Pharmacol. 54, 157-167 (2002).
12. Johnson MD, Zuo H. Lee KH et al.: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85. 151-159 (2004).
13. Stearns V, Johnson MD, Rae JM et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95, 1758-1764 (2003).
14. Bradford LD: CYPD2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243 (2002).
15. Jin Y, Desta Z, Stearns V et al.: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 97, 30-39 (2005).
16. Goetz W, Rae JM, Suman VJ et al.: Pharmacogenetics of tamoxifen biotransfotmation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
17. Ingle JN, Suman VJ, Maiward JA et al.: Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res. Treat. 98, 217-222 (2006).
18. Bonanni B, Macis D. Maisonneuve P et al: Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J. Clin. Oncol. 24, 3708-3709 (2006).
19. Wegman P, Vatnikka L, Stal O et al.: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7, R284-R290 (2005).
20. Rae JM, Goetz MP, Hayes DF et al.: CYP2D6 genotype and tamoxifen response. Breast Cancer Res. 7, E6 (2005).
21. Nowell SA, Ahn J, Rae JM et al.: Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 91, 249-258 (2005).
22. Borges S, Desta Z, Li L et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol Ther. 80, 61-74 (2006).
23. Loprinzi CL, Kugler JW, Sloan JA et al.: Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356, 2059-2063 (2000).
24. Loprinzi CL, Sloan JA, Perez EA et al: Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin. Oncol. 20, 1578-1583 (2002).
25. Steams V, Beebe KL, Iyengar M, Dube E: Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 289, 2827-2834 (2003).
26. Goetz MP, Knox SK, Suman VJ et al.: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. (2006) (Epub ahead of print).
27. Coombes RC, Hall E. Gibson LJ et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081-1092 (2004).